Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 9,409

Document Document Title
WO/2008/117815A1
An inhibitor for cell death caused by endoplasmic reticulum stress or oxidation stress which contains, as the active ingredient, a carbazole derivative represented by the following general formula (I) or a pharmaceutically acceptable sal...  
WO/2008/117481A1
It is intended to provide a moisturizer, an antiaging agent, an antiobesity agent, an antioxidant agent and an antiinflammatory agent which contain an active ingredient originating in a natural material and are applicable to a skin prepa...  
WO/2008/114660A1
[PROBLEMS] To provide: a composition derived from a natural plant and having a antioxidant activity, specifically a composition particularly for oral applications which is derived from a natural plant having a characteristic bitter or as...  
WO/2008/113134A1
The present invention relates to a method for transplanting a kidney from a donor to a recipient. In a preferred embodiment, the method involves administering an iron chelator to the donor prior to harvesting the kidney and/or administer...  
WO/2008/115433A1
A relatively non-toxic desazadesferrithiocin analog having the formula (I): wherein: R1, R2, R4 and R5 may be the same or different and may be H, straight or branched chain alkyl having up to 14 carbon atoms, e.g., methyl, ethyl, propyl ...  
WO/2008/111244A1
An external preparation for the skin, a cell activator, a collagen production promoter, a hyaluronic acid production promoter, an antioxidant agent, a melanin formation inhibitor, a fat accumulation inhibitor, an adiponectin production p...  
WO/2008/106715A1
The invention provides oxazinyl isoflavonoid compounds and compositions containing same, methods for their preparation and their use as therapeutic agents particularly as cardioprotective, anti-inflammatory, anti-oxidant and chemotherape...  
WO/2008/105325A1
Disclosed is a beverage which can exert various useful functions of arginine, is easy to drink and has excellent stability. Specifically disclosed is a beverage containing 0.5 to 10% by weight of citrulline, 0.1 to 40% by weight of a sug...  
WO/2008/105392A1
Disclosed is a substance for inhibiting cell death, which is effective as a prophylactic or therapeutic agent for the progress of a condition of a disease whose of progress or exacerbation is associated with cell death. Specifically disc...  
WO/2008/102584A1
Disclosed is a novel compound which can be used as a pharmaceutical agent, a cosmetic, a health food, a food additive or the like. Specifically disclosed is a flavanol compound shown by the formula (1). (1)  
WO/2008/102467A1
Disclosed is an external preparation for the skin, which is characterized by comprising a blue-green alga belonging to the family Chroococcus or an extract thereof. Also disclosed is a functional oral composition characterized by compris...  
WO/2008/101195A2
The present invention is directed to compounds, compositions, and methods for halting or reversing the effects of chemoresistance in neoplastic diseases. In particular the use of hydroxylamines is described.  
WO/2008/099924A1
Disclosed are: a novel strain of an alga belonging to the genus Chlorella, which has a high proliferation ability in culture in the darkness, and has a high chlorophyll content and a high active oxygen scavenging effect; and a compositio...  
WO/2008/101195A4
The present invention is directed to compounds, compositions, and methods for halting or reversing the effects of chemoresistance in neoplastic diseases. In particular the use of hydroxylamines is described.  
WO/2008/099144A2
The invention relates to the use of TGF-beta stimulating agents, and in particular members of the triphenylethylene class of pharmaceutical agents, for the prevention, prophylaxis, treatment or amelioration of symptoms of cardiovascular ...  
WO/2008/101195A3
The present invention is directed to compounds, compositions, and methods for halting or reversing the effects of chemoresistance in neoplastic diseases. In particular the use of hydroxylamines is described.  
WO/2008/099804A1
Disclosed is a therapeutic agent for diabetic cataract which has effective delay activity on the progress of diabetic cataract. The therapeutic agent comprises an antioxidant agent capable of preventing the impaired oxidation in the reti...  
WO/2008/095366A1
A porphyrin derivative and its pharmaceutical acceptable salt and its preparation method. The said porphyrin derivative is M-5,10,15,20-tetra[3-ethylene polyol monomethyl ether-substituted -phenyl]porphyrin, in which M is one of Fe, Mn, ...  
WO/2008/094061A1
The invention relates to biology and medicine, in particular, it can be used in medicine for preparing a pharmacological composition used for accelerated healing of wounds and the damages by means of addressed (directed) delivery of biol...  
WO/2008/095093A2
This invention provides a method of improving glutathione (GSH) concentrations, both intra and extra-cellularly, in animals, thereby improving the cellular function of the immune and other bodily organ functions. The invention is directe...  
WO/2008/094062A1
The invention relates to pharmacology, medicine and oncology, in particular, to a class of chemical compounds, the structure of which corresponds to formula (I) and which can be used in pharmaceutical compositions for preventing and trea...  
WO/2008/093302A3
The present invention is directed to a method for decreasing inflammation and oxidative stress in a mammal comprising; administration to a mammal a composition comprising a glucose antimetabolite; and wherein said composition comprises a...  
WO/2008/093302A2
The present invention is directed to a method for decreasing inflammation and oxidative stress in a mammal comprising; administration to a mammal a composition comprising a glucose antimetabolite; and wherein said composition comprises a...  
WO/2008/095093A3
This invention provides a method of improving glutathione (GSH) concentrations, both intra and extra-cellularly, in animals, thereby improving the cellular function of the immune and other bodily organ functions. The invention is directe...  
WO/2008/090749A1
Disclosed is an agent for the modification of an SH group or a cell-protecting agent, which can selectively react particularly with a highly reactive SH group in an intracellular environment where SH-containing proteins having various ty...  
WO/2008/088047A1
Disclosed is a method for producing a glycoside of a flavonoid, which comprises the step of reacting the flavonoid and a sugar donor with an enzymatic agent having a glycosylation activity and derived from a bacterium belonging to the ge...  
WO/2008/084828A1
Disclosed is a method for commercially and efficiently producing a coenzyme Q10 particle having high content and excellent powder flow characteristics by simple facilities and simple operations. Specifically disclosed is a method for pro...  
WO/2008/079993A3
The present invention provides methods of reducing the cytotoxic effects of nitric oxide and sulfides comprising coadministering nitric oxide with sulfide. In addition, the present invention provides novel pharmaceutical compositions com...  
WO/2008/079993A2
The present invention provides methods of reducing the cytotoxic effects of nitric oxide and sulfides comprising coadministering nitric oxide with sulfide. In addition, the present invention provides novel pharmaceutical compositions com...  
WO/2008/074091A1
The invention relates to radioprotectors of formula (I), processes for their preparation and their use in protecting biological materials from radiation damage. In diagnostic and therapeutic radiology, particularly in cancer radiotherapy...  
WO2008036387A8
Endothelial dysfunction (ED) is associated with a number of diseases and disorders. Agonists of the non-proteolytically activated thrombin receptor can be used in methods to treat ED or ED-related diseases and disorders.  
WO/2008/076000A1
The invention relates to the use of acizol in the form of an agent for preventing and treating intoxications produced by combustion products, thermal destruction and by neurotoxic substances. The high efficiency of acizol for comprehensi...  
WO/2008/070741A1
The present invention is directed to compositions and methods for enhancing the survivability of, and/or reducing damage to, cells, tissues, organs, and organisms, particularly under ischemic or hypoxic conditions.  
WO/2008/064393A1
There is described a method for treating envenomation of a mammal in which inhibition of lymphatic flow is desirable. The method comprises administering an effective amount of at least one nitric oxide releasing or generating compound to...  
WO2007132418B1
The present invention concerns to the use of salicylate in the treatment of mammal intoxications caused by the herbicide paraquat (PQ). It was achieved, for the first time, 100% of survival 30 days after the administration to Wistar rats...  
WO/2008/066862A2
The present invention relates to novel methods of treating or reducing the likelihood of developing gadolinium toxicity by administering to a patient a metal chelator before, concurrently with, or after exposure to gadolinium. The novel ...  
WO/2008/066370A1
There is disclosed a method of extraction of Nephelium lappaceum extracts, a composition of phenolic compounds, with high free radical scavenging activity. The extract is characterised by its radical scavenging activity with IC50 (effect...  
WO/2008/065247A1
Class A beta-lactamase may be used for reducing side- effects in the intestine associated with antibiotic therapy with a combination of beta-iactam antibiotic and beta- lactamase inhibitor.  
WO/2008/065891A1
Administration of either a tocopherol represented by the general formula (1) or a tocotrienol compound ester derivative before or after exposure to radiation is effective in preventing or treating health disorders caused by the radiation...  
WO/2008/062852A1
It is intended to provide a composition for neutralizing the exotoxin of enterohemorrhagic Escherichia coli which comprises a less expensive and easily available source as the main component. This object has been achieved by finding out ...  
WO/2008/062861A1
Disclosed are: an extract powder of an indigo-containing plant, which has a low hygroscopic property, excellent fluidability and high storage stability; a method for producing the extract powder; and a composition comprising the extract ...  
WO/2008/058988A1
The use of a compound of formula (I), is disclosed in treating and/or preventing 5 chemotherapy-induced peripheral neurotoxicity (CIPN). The invention includes pharmaceutical compositions wherein the compound of formula (I) is present in...  
WO/2008/059905A1
It is intended to provide a raw material for an oral product which is capable of exhibiting various functions of an active oxygen eliminating ability, antiallergy and improvement of the skin, useful for beautification and health, and can...  
WO2007045959A8
The present invention is directed to antioxidative and antiproliferative agents containing North American ginseng (proprietary extract HTlOOl) alone or in combination with Ginkgo biloba (GB), Saint John's Wort (SJW), ginkgolides, flavono...  
WO/2008/053920A1
It is intended to provide a granular composition comprising an oily component (A), which contains a hardly water-soluble physiologically active substance and is polydispersed while forming domains in a matrix made of a water-soluble fill...  
WO/2008/049227A1
The present invention provides a multimeric form of a Tie 2 binding peptide monomer, wherein the multimeric form has Tie 2 agonist activity. The multimeric form, preferably a tetramer, stimulates angiogenesis and promotes wound healing. ...  
WO/2008/050789A1
The object is to demonstrate the myocardial protection effect of interleukin-11 in vivo and provide a prophylactic or therapeutic agent for a heart disease or the like comprising interleukin-11 as an active ingredient. Interleukin-11 has...  
WO/2008/051795A3
A water-insoluble cellulose derivative, such as ethyl cellulose is useful for preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal and in particular for influencing the level Stearoyl-CoA Desaturase-1 ...  
WO/2008/051795A2
A water-insoluble cellulose derivative, such as ethyl cellulose is useful for preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal and in particular for influencing the level Stearoyl-CoA Desaturase-1 ...  
WO/2008/050754A1
Disclosed is an intracerebral oxidation inhibitor which can prevent the occurrence of dementia and is effective for early treatment. Specifically disclosed are: an intracerebral oxidation inhibitor comprising a peptide composed of Leu an...  

Matches 551 - 600 out of 9,409